(MENAFN- America News Hour) Global Xerostomia (Dry Mouth) Therapeutics
Market Key Insights
During the forecast period of 2022-2031, the global xerostomia (dry mouth) therapeutics market acquired a value of ~USD 680 million in 2021, by expanding at a CAGR of ~6%. Major key factors propelling the growth of the xerostomia (dry mouth) therapeutics market worldwide are the high frequency of dry mouth conditions and insufficient saliva production in adults, mainly those 50 and older.
Market Definition of
Xerostomia (Dry Mouth) Therapeutics
A dry mouth is a condition known as xerostomia. The salivary glands become unable to produce the desired volume of saliva in the mouth due to this ailment. However, this isn't the only factor. Xerostomia can also happen when you don't drink enough fluids, sleep with your mouth open, spend a lot of time outside in the sun, have drug side effects, etc. The salivary glands may be affected by diseases including diabetes and HIV/AIDS. Thus, xerostomia may result from this as well. Another factor in women that might cause xerostomia is menopause.
Global
Xerostomia (Dry Mouth) Therapeutics
Market: Growth Drivers
The introduction of numerous cutting-edge xerostomia therapeutics products by the top market players is largely responsible for the expansion of the global xerostomia (dry mouth) therapeutics market. For instance, Colgate-Palmolive Company and 3Shape will collaborate on January 24, 2022, to roll out Colgate Illuminator, a cutting-edge, custom tooth-whitening instrument, throughout dentist offices in the United States.
Browse Full Report Along With Facts and Figures @
On the other hand, the market expansion is also attributable to a number of technological developments in the area of xerostomia treatments, which are anticipated to fuel market expansion. For instance, Colgate-Palmolive Company and 3Shape will collaborate on January 24, 2022, to roll out Colgate Illuminator, a cutting-edge, custom tooth-whitening instrument, throughout dentist offices in the United States.
The global xerostomia (dry mouth) therapeutics market is also estimated to grow majorly on account of the following:
Rising prevalence of cancer Rising incidence of diabetes, hypertension Growing geriatric population Increasing adoption of chemotherapy and radiotherapy
Global
Xerostomia (Dry Mouth) Therapeutics
Market: Restraining Factor
Treatment with finger-prick autologous blood may prove to be a barrier to the market's expansion. An innovative procedure called finger-prick autologous blood (FAB) is viewed as a more effective and creative way to treat and combat dry mouth.
Know More About the Complete Study @
Global Xerostomia (Dry Mouth) Therapeutics
Market Segmentation
By
Type ( Artificial Saliva/Saliva Substitutes, and Salivary Stimulants)
By expanding with a consistent CAGR during the forecast period, the artificial saliva category is anticipated to have the highest market share. The availability of efficient treatments and the simplicity of product handling might be credited with this rise. Artificial saliva is a liquid or aerosol that can be used as a gel or sprayed into the mouth. This product is not only simple to use but also produces results that are just as effective. In the United States (US), xerostomia, or dry mouth, affects 24 million people, 8 million of whom have moderate to severe symptoms.
The rising number of patients raises the need for artificial saliva and further leads to the expansion of the segment.
By Product ( Drugs, Salivary Pens, and Others) By Distribution Channel ( Hospital Pharmacies, Retail Pharmacies, Drug Store, and Online Pharmacies) By Region
The Asia Pacific region's market is anticipated to expand significantly over the course of the forecast period as a result of rising healthcare funding, increased treatment awareness, and an increase in the incidence of diseases that cause dry mouth, such as Parkinson's disease, cancer, diabetes mellitus, and HIV. In the Asia Pacific region, there were 5.8 million HIV infections on average in 2019.
Download Sample PDF Copy of this Report to understand structure of the complete report (Including Full TOC, Table & Figures) @
The market research report on global xerostomia (dry mouth) therapeutics also includes the market size, market revenue, Y-o-Y growth, and key player analysis applicable for the market in North America (U.S., and Canada), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), and Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa).
Key Market Players Featured in the Global Xerostomia (Dry Mouth) Therapeutics Market
Some of the key players of the global xerostomia (dry mouth) therapeutics market are Colgate-Palmolive Company, EUSA Pharma, GlaxoSmithKline plc, Forward Science, OraPharma (Bausch Health Companies Inc.), Parnell Pharmaceuticals, Inc., Eisai Co., Ltd., Sun Pharmaceuticals Industries Ltd., Saliwel Ltd., and Mission Pharmaceutical Company among others.
About Kenneth Research:
Kenneth Research, which is a leading reseller for strategic market research and consulting services, aims to help conglomerates, executives, and industries to take wise decisions for their businesses as well as for their future marketing strategy, expansion and investment among others. We provide unbiased, unparalleled market insights and industry analysis and believe that our expertise in the field of market research can help businesses to expand to its new horizon. Our team of research analysts can provide businesses a right guidance at the right time, while our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties.
Contact for more Info:
AJ Daniel
Email:
U.S. Phone: +1 313 462 0609